The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations
Subscribe To Our Newsletter & Stay Updated
